沃森生物(300142.SZ)：子公司收到13价肺炎结合疫苗埃及上市许可证

Core Viewpoint - Watson Bio's subsidiary, Yuxi Watson Biotechnology Co., Ltd., has received a marketing authorization for its 13-valent pneumococcal polysaccharide conjugate vaccine from the Egyptian Drug Authority, marking a significant milestone for the company's international expansion [1] Group 1: Product Approval - The 13-valent pneumococcal conjugate vaccine is approved for use in infants and children aged 6 weeks to under 5 years [1] - The vaccine is designed to prevent infections caused by 13 serotypes of pneumococcus, which include types 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F [1] - This vaccine was initially approved for sale in China in 2020, indicating the company's established presence in the domestic market prior to its international approval [1]